Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection

Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d...

Full description

Bibliographic Details
Main Authors: Katherine M. Dominy, Michelle Willicombe, Tariq Al Johani, Hannah Beckwith, Dawn Goodall, Paul Brookes, H. Terence Cook, Tom Cairns, Adam McLean, Candice Roufosse
Format: Article
Language:English
Published: Elsevier 2019-01-01
Series:Kidney International Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024918302031
id doaj-880cfddd007d4d088228bc0afb92e92a
record_format Article
spelling doaj-880cfddd007d4d088228bc0afb92e92a2020-11-25T00:08:19ZengElsevierKidney International Reports2468-02492019-01-0141148158Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of RejectionKatherine M. Dominy0Michelle Willicombe1Tariq Al Johani2Hannah Beckwith3Dawn Goodall4Paul Brookes5H. Terence Cook6Tom Cairns7Adam McLean8Candice Roufosse9Centre for Inflammatory Diseases, Imperial College, London, UKCentre for Inflammatory Diseases, Imperial College, London, UKKing Saud University, Riyadh, Saudi ArabiaImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKCentre for Inflammatory Diseases, Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKImperial College Healthcare NHS Trust, London, UKCentre for Inflammatory Diseases, Imperial College, London, UK; Imperial College Healthcare NHS Trust, London, UK; Correspondence: Candice Roufosse, Imperial College, Hammersmith Campus, Commonwealth Building 9th Floor (Centre for Inflammatory Diseases), Du Cane Road, London, W12 0HS, UK.Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) is unknown. We investigated the transcript levels of genes associated with AbMR in C4d+ WER biopsies from both ABO-compatible and incompatible renal transplant patients. Methods: RNA was extracted from formalin-fixed paraffin-embedded renal transplant biopsies (n = 125) and gene expression analysis of 35 AbMR-associated transcripts carried out using the NanoString nCounter system. Results: AbMR-associated transcripts were significantly increased in samples with AbMR or suspicious AbMR. A subgroup of 17 of 35 transcripts that best distinguished AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ WER samples. There was no differential expression between C4d-negative and C4d+ WER from both ABO-incompatible and -compatible transplants. The geometric mean of 17 differentially expressed genes was used to assign the C4d+ WER biopsies a high- or low-AbMR transcript score. Follow-up biopsies showed AbMR within 1 year of initial biopsy in 5 of 7 high-AbMR transcript patients but only 2 of 46 low-AbMR transcript patients. In multivariate logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were associated with increased odds for biopsy-proven AbMR on follow-up (P = 0.032, odds ratio 16.318), whereas factors including donor-specific antibody (DSA) status and time since transplantation were not. Conclusion: Gene expression analysis in C4d+ WER samples has the potential to identify patients at higher risk of developing AbMR. Keywords: antibody mediated rejection, C4d, kidney, molecular, transplant rejectionhttp://www.sciencedirect.com/science/article/pii/S2468024918302031
collection DOAJ
language English
format Article
sources DOAJ
author Katherine M. Dominy
Michelle Willicombe
Tariq Al Johani
Hannah Beckwith
Dawn Goodall
Paul Brookes
H. Terence Cook
Tom Cairns
Adam McLean
Candice Roufosse
spellingShingle Katherine M. Dominy
Michelle Willicombe
Tariq Al Johani
Hannah Beckwith
Dawn Goodall
Paul Brookes
H. Terence Cook
Tom Cairns
Adam McLean
Candice Roufosse
Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
Kidney International Reports
author_facet Katherine M. Dominy
Michelle Willicombe
Tariq Al Johani
Hannah Beckwith
Dawn Goodall
Paul Brookes
H. Terence Cook
Tom Cairns
Adam McLean
Candice Roufosse
author_sort Katherine M. Dominy
title Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
title_short Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
title_full Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
title_fullStr Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
title_full_unstemmed Molecular Assessment of C4d-Positive Renal Transplant Biopsies Without Evidence of Rejection
title_sort molecular assessment of c4d-positive renal transplant biopsies without evidence of rejection
publisher Elsevier
series Kidney International Reports
issn 2468-0249
publishDate 2019-01-01
description Introduction: Immunohistochemical staining for C4d in peritubular capillaries has been part of antibody-mediated rejection (AbMR) definition in the Banff Classification for Allograft Pathology since 2003. However, it has limited sensitivity and specificity, therefore the clinical significance of C4d-positive biopsies without evidence of rejection (C4d+ WER) is unknown. We investigated the transcript levels of genes associated with AbMR in C4d+ WER biopsies from both ABO-compatible and incompatible renal transplant patients. Methods: RNA was extracted from formalin-fixed paraffin-embedded renal transplant biopsies (n = 125) and gene expression analysis of 35 AbMR-associated transcripts carried out using the NanoString nCounter system. Results: AbMR-associated transcripts were significantly increased in samples with AbMR or suspicious AbMR. A subgroup of 17 of 35 transcripts that best distinguished AbMR from C4d-negative biopsies without evidence of rejection was used to study C4d+ WER samples. There was no differential expression between C4d-negative and C4d+ WER from both ABO-incompatible and -compatible transplants. The geometric mean of 17 differentially expressed genes was used to assign the C4d+ WER biopsies a high- or low-AbMR transcript score. Follow-up biopsies showed AbMR within 1 year of initial biopsy in 5 of 7 high-AbMR transcript patients but only 2 of 46 low-AbMR transcript patients. In multivariate logistic regression analysis, elevated transcript levels in a C4d+ WER biopsy were associated with increased odds for biopsy-proven AbMR on follow-up (P = 0.032, odds ratio 16.318), whereas factors including donor-specific antibody (DSA) status and time since transplantation were not. Conclusion: Gene expression analysis in C4d+ WER samples has the potential to identify patients at higher risk of developing AbMR. Keywords: antibody mediated rejection, C4d, kidney, molecular, transplant rejection
url http://www.sciencedirect.com/science/article/pii/S2468024918302031
work_keys_str_mv AT katherinemdominy molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT michellewillicombe molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT tariqaljohani molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT hannahbeckwith molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT dawngoodall molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT paulbrookes molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT hterencecook molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT tomcairns molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT adammclean molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
AT candiceroufosse molecularassessmentofc4dpositiverenaltransplantbiopsieswithoutevidenceofrejection
_version_ 1725415807393988608